Xiamen Humanity Hospital
Bone cancer treatment cost in China typically ranges from $9,500 to $22,500 for bone resection and approximately Price on request to Price on request for reconstruction with implant replacement. Total expenses depend on tumor complexity, reconstruction materials, and clinic tier. Patients often achieve 60% to 80% savings compared to the United States. Top treatment hubs include Guangzhou, Xiamen, and Beijing.
Typical Bone Cancer Treatment Costs in China
Bookimed Expert Insight: Patients with late-stage bone cancer benefit from advanced technologies like cryosurgery or NanoKnife at JCI-accredited facilities. Fuda Cancer Hospital specializes in these minimally invasive approaches for complex cases. For those requiring precise radiation, multidisciplinary centers in Xiamen offer expertise in IMRT and SBRT. These tertiary hospitals utilize clinical trials to provide access to emerging therapies efficiently.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Chemotherapy for breast cancer | from $14,800 | from $1,200 | from $15,000 |
| Bone resection | from $9,500 | from $12,000 | from $25,000 |
| Bone deformity correction surgery | from $13,500 | from $2,500 | from $30,000 |
| Actinium-225 Therapy | from $13,800 | from $22,955 | from $55,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Medical treatment for bone cancer in China centers on multidisciplinary protocols. These include limb-salvage surgery, advanced 3D-printed reconstructions, and specialized chemotherapy. JCI-accredited centers also utilize minimally invasive options like cryosurgery and NanoKnife. Integrated traditional Chinese medicine helps manage symptoms and treatment side effects.
Bookimed Expert Insight: China offers a unique advantage for patients seeking alternatives to traditional chemotherapy through hospitals like Fuda. This facility has treated over 30,000 international patients by applying over 10 types of minimally invasive therapies. These options target late-stage cancers while potentially reducing the systemic burden on the patient.
Patient Consensus: Patients emphasize the importance of early expert consultation to maximize chances for limb-sparing surgery. Practical concerns often focus on the logistical burden of traveling to major urban centers and coordinating extensive rehabilitation.
China provides advanced minimally invasive bone cancer treatments through JCI-accredited facilities. Specialized centers utilize localized needle-based ablation and targeted vascular therapies. These technologies aim to destroy tumors while preserving bone structure. Precision radiotherapy and cell therapies address complex primary or metastatic cases.
Bookimed Expert Insight: Data from Fuda Cancer Hospital shows a preference for combining multiple minimally invasive therapies. They often use cryosurgery and vascular intervention instead of traditional chemotherapy. This approach serves a high volume of over 30,000 international patients. It is particularly effective for late-stage patients seeking to maintain quality of life.
Patient Consensus: Patients note that modern limb-sparing surgery is a major alternative to amputation. They emphasize having a biopsy plan created by the same team that performs surgery.
Traditional Chinese Medicine (TCM) serves as a supportive therapy in Chinese bone cancer care. It focuses on pain relief and managing chemotherapy side effects. Facilities like Xiamen Humanity Hospital integrate these modalities alongside precision radiotherapy. TCM never replaces surgery or essential oncology protocols.
Bookimed Expert Insight: Chinese oncology centers often combine specialized TCM rehabilitation with high-tech interventions. For instance, Xiamen Humanity Hospital employs over 460 doctors and manages 1,000,000 patients annually. This massive scale allows for highly specialized integrative departments. These units focus specifically on balancing systemic wellness with advanced technologies like IMRT and VMAT.
Patient Consensus: Patients emphasize using TCM to feel stronger and improve digestion rather than targeting the tumor. They note that informing the oncology team about every herb is vital to avoid drug interactions.
China offers specialized bone cancer care at JCI-accredited oncology centers and large tertiary hospitals. Facilities in Guangzhou and Xiamen provide advanced treatments like NanoKnife and cryosurgery. These centers maintain dedicated international departments to support foreign patients with translation, visa logistics, and multidisciplinary treatment planning.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out for its massive scale. It manages 1,000,000 patients annually and has 46 clinical departments. This high volume often translates to significant expertise in handling rare drug trials. Patients seeking unique interventions may find these clinical trial-level capabilities highly beneficial compared to standard oncology centers.
Patient Consensus: Patients emphasize the importance of having biopsy slides re-read by expert pathologists at high-volume sarcoma centers. They note that specialized support and English-speaking coordination are as vital as the surgery for a smooth recovery.
Chinese hospitals coordinate bone cancer work-ups through a centralized Multidisciplinary Team (MDT) framework. This protocol integrates orthopedic surgery, oncology, and radiology at Class 3 Grade A centers. These hubs follow national clinical pathways to ensure diagnostic imaging and biopsy align with future surgical goals.
Bookimed Expert Insight: Clinical volume significantly impacts diagnostic speed in China. Xiamen Humanity Hospital serves approximately 1,000,000 patients annually across 47 departments. This high volume allows tertiary centers to stabilize diagnostic timelines. These facilities often offer advanced precision radiotherapy like IMRT or VMAT. Choosing a high-capacity center ensures your radiology and pathology reviews are batched efficiently.
Patient Consensus: Patients note it is essential to bring original imaging disks rather than just printed reports. They emphasize that the biopsy must be performed at the same hospital where the final surgery occurs.
Chinese oncology centers provide integrated logistical workflows to support overseas bone cancer patients during complex treatments. Facilities like Fuda Cancer Hospital utilize dedicated international departments to manage medical visas, airport transfers, and 24/7 multilingual translation. These services streamline navigation through large-scale medical campuses in major cities.
Bookimed Expert Insight: Quality signals in China often correlate with high patient volumes and international accreditations. For instance, Xiamen Humanity Hospital serves approximately 1,000,000 patients annually. Meanwhile, Fuda Cancer Hospital maintains JCI accreditation while treating people from over 100 countries. Choosing a JCI-accredited facility ensures that logistical protocols meet global safety and communication standards.
Patient Consensus: Patients note that while hospitals are highly efficient at processing diagnostic tests, families are often expected to help with daily tasks. Having a dedicated international coordinator is essential for navigating payment systems and large hospital buildings.